<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41010890</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>18</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Recurrence of Glomerular Diseases (GN) After Kidney Transplantation: A Narrative Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">6686</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm14186686</ELocationID><Abstract><AbstractText>Recurrence of the original glomerular disease (GN) poses a significant threat to kidney transplant function and longevity. The probability and severity of this recurrence vary, with C3 glomerulopathy and certain forms of FSGS exhibiting particularly high rates. Kidney transplant GN recurrence risk hinges on the characteristics of the initial GN, recipient/donor genetics, recipient age, donor type, end-stage kidney disease (ESRD) progression rate, and proteinuria levels. Standard immunosuppression has limited efficacy in preventing primary disease recurrence; however, agent selection and induction therapy can influence the risk for specific GNs. Diagnosing recurrent GN involves a comprehensive approach, including clinical evaluation, laboratory tests (such as proteinuria, hematuria, and specific biomarkers like anti-PLA2R for membranous nephropathy or complement for C3G), and, critically, an allograft biopsy analyzed with light, immunofluorescence, and electron microscopy. Treatment strategies are evolving towards targeted therapies, such as rituximab for antibody-mediated GN and complement inhibitors for C3G, moving away from broad immunosuppression. This narrative literature review provides practical monitoring algorithms for post-transplant settings, synthesizing information on the incidence, predictors, diagnostic strategies, and therapeutic options for various glomerular disease subtypes. The methodology involved searching MEDLINE, Embase, and Cochrane databases from 1996 to 2025, prioritizing systematic reviews, cohort studies, registries, and interventional reports. Eligibility criteria included adult transplant recipients and English-language reports on recurrent glomerular disease outcomes, excluding most single-patient case reports. Limitations include potential selection bias, omission of relevant studies, and the absence of a formal risk-of-bias assessment or meta-analysis. The evidence base is heterogeneous, with inconsistent outcome reporting and scarce randomized controlled trials. Future efforts should focus on developing predictive biomarkers, standardizing diagnostic and response criteria, conducting multicenter prospective cohorts and pragmatic trials, and creating shared registries with harmonized data.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koirala</LastName><ForeName>Abbal</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2154-0893</Identifier><AffiliationInfo><Affiliation>Division of Nephrology, Johns Hopkins School of Medicine, 5501 Hopkins Bayview Circle, Floor 1, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Aditi</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0009-2164-8870</Identifier><AffiliationInfo><Affiliation>Division of Nephrology, Johns Hopkins School of Medicine, 5501 Hopkins Bayview Circle, Floor 1, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geetha</LastName><ForeName>Duvuru</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Johns Hopkins School of Medicine, 5501 Hopkins Bayview Circle, Floor 1, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ANCA-associated vasculitis (AAV)</Keyword><Keyword MajorTopicYN="N">C3 glomerulopathy (C3G)</Keyword><Keyword MajorTopicYN="N">IgA nephropathy (IgAN)</Keyword><Keyword MajorTopicYN="N">anti-glomerular basement membrane disease (anti-GBM disease)</Keyword><Keyword MajorTopicYN="N">focal segmental glomerulosclerosis (FSGS)</Keyword><Keyword MajorTopicYN="N">glomerular disease (GN)</Keyword><Keyword MajorTopicYN="N">membranoproliferative glomerulonephritis (MPGN)</Keyword><Keyword MajorTopicYN="N">membranous nephropathy (MN)</Keyword><Keyword MajorTopicYN="N">recurrent lupus nephritis (RLN)</Keyword></KeywordList><CoiStatement>A. Koirala serves on the advisory board for Calliditas Pharmaceuticals, focusing on targeted release budesonide. While this relationship is disclosed for transparency, A. Koirala asserts that it did not influence the content, analysis, or conclusions of this review paper. Duvuru Geetha has received consultancy fees from Calliditas, Vera therapeutics, Travere therapeutics, Amgen, Otsuka and Boeringer Ingelheim. The authors declare no conflict of interest for the review paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>1</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41010890</ArticleId><ArticleId IdType="pmc">PMC12471057</ArticleId><ArticleId IdType="doi">10.3390/jcm14186686</ArticleId><ArticleId IdType="pii">jcm14186686</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lim W.H., Shingde M., Wong G. Recurrent and de novo Glomerulonephritis After Kidney Transplantation. Front. Immunol. 2019;10:1944. doi: 10.3389/fimmu.2019.01944.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01944</ArticleId><ArticleId IdType="pmc">PMC6702954</ArticleId><ArticleId IdType="pubmed">31475005</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvadori M., Rosso G. Recurrence of primary glomerular diseases after kidney transplantation: Incidence, predictors, characteristics and treatment. Transplantology. 2025;6:14. doi: 10.3390/transplantology6020014.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/transplantology6020014</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayrdorfer M., Liefeldt L., Wu K., Rudolph B., Zhang Q., Friedersdorff F., Lachmann N., Schmidt D., Osmanodja B., Naik M.G., et al. Exploring the complexity of death-censored kidney allograft failure. J. Am. Soc. Nephrol. 2021;32:1513&#x2013;1526. doi: 10.1681/ASN.2020081215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2020081215</ArticleId><ArticleId IdType="pmc">PMC8259637</ArticleId><ArticleId IdType="pubmed">33883251</ArticleId></ArticleIdList></Reference><Reference><Citation>Saran R., Robinson B., Abbott K.C., Bragg-Gresham J., Chen X., Gipson D., Gu H., Hirth R.A., Hutton D., Jin Y., et al. US renal data system 2019 annual data report: Epidemiology of kidney disease in the United States. Am. J. Kidney Dis. 2020;75((Suppl. 1)):A6&#x2013;A7. doi: 10.1053/j.ajkd.2019.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2019.09.003</ArticleId><ArticleId IdType="pubmed">31704083</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen P.J., Chadban S.J., Craig J.C., Lim W.H., Allen R.D.M., Clayton P.A., Teixeira-Pinto A., Wong G. Recurrent glomerulonephritis after kidney transplantation: Risk factors and allograft outcomes. Kidney Int. 2017;92:461&#x2013;469. doi: 10.1016/j.kint.2017.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.03.015</ArticleId><ArticleId IdType="pubmed">28601198</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguiar R., Bourmpaki E., Bunce C., Coker B., Delaney F., de Jongh L., Oliveira G., Weir A., Higgins F., Spiridou A., et al. Incidence, Risk Factors, and Effect on Allograft Survival of Glomerulonephritis Post-transplantation in a United Kingdom Population: Cohort Study. Front. Nephrol. 2022;2:923813. doi: 10.3389/fneph.2022.923813.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneph.2022.923813</ArticleId><ArticleId IdType="pmc">PMC10479671</ArticleId><ArticleId IdType="pubmed">37675026</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S.H., Kennard A.L., Walters G.D. Recurrent glomerulonephritis following renal transplantation and impact on graft survival. BMC Nephrol. 2018;19:344. doi: 10.1186/s12882-018-1135-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-018-1135-7</ArticleId><ArticleId IdType="pmc">PMC6278033</ArticleId><ArticleId IdType="pubmed">30509213</ArticleId></ArticleIdList></Reference><Reference><Citation>Alawieh R., Boonpheng B., Blosser C.D. Recurrence of glomerulonephritis after kidney transplant. Nephrol. Dial. Transplant. 2022;37:2090&#x2013;2092. doi: 10.1093/ndt/gfab345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfab345</ArticleId><ArticleId IdType="pubmed">35108387</ArticleId></ArticleIdList></Reference><Reference><Citation>Uffing A., P&#xe9;rez-Sa&#xe9;z M.J., Jouve T., Bugnazet M., Malvezzi P., Muhsin S.A., Lafargue M.-C., Reindl-Schwaighofer R., Morlock A., Oberbauer R., et al. Recurrence of IgA nephropathy after kidney transplantation in adults. Clin. J. Am. Soc. Nephrol. 2021;16:1247&#x2013;1255. doi: 10.2215/CJN.00910121.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.00910121</ArticleId><ArticleId IdType="pmc">PMC8455056</ArticleId><ArticleId IdType="pubmed">34362788</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. 2009;9((Suppl. 3)):S1&#x2013;S155. doi: 10.1111/j.1600-6143.2009.02834.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2009.02834.x</ArticleId><ArticleId IdType="pubmed">19845597</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawabe M., Yamamoto I. Current status and perspectives on recurrent IgA nephropathy after kidney transplantation. Nephron. 2023;147((Suppl. 1)):9&#x2013;13. doi: 10.1159/000530341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000530341</ArticleId><ArticleId IdType="pubmed">36966530</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;ger C., Stampf S., Molyneux K., Barratt J., Golshayan D., Hadaya K., Huynh-Do U., Binet F.-I., Mueller T.F., Koller M., et al. Recurrence of IgA nephropathy after kidney transplantation: Experience from the Swiss transplant cohort study. BMC Nephrol. 2022;23:178. doi: 10.1186/s12882-022-02802-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-022-02802-x</ArticleId><ArticleId IdType="pmc">PMC9088042</ArticleId><ArticleId IdType="pubmed">35538438</ArticleId></ArticleIdList></Reference><Reference><Citation>Engen R.M., Bartosh S.M., Smith J.M., Perkins J.D., Harshman L.A. Risk for graft loss in pediatric and young adult kidney transplant recipients due to recurrent IgA nephropathy. Am. J. Transplant. 2024;24:37&#x2013;45. doi: 10.1016/j.ajt.2023.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajt.2023.08.007</ArticleId><ArticleId IdType="pubmed">37595842</ArticleId></ArticleIdList></Reference><Reference><Citation>Bednarova K., Mj&#xf8;en G., Hruba P., Modos I., Voska L., Kollar M., Viklicky O. A novel prognostic nomogram predicts premature failure of kidney allografts with IgA nephropathy recurrence. Nephrol. Dial. Transplant. 2023;38:2627&#x2013;2636. doi: 10.1093/ndt/gfad097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfad097</ArticleId><ArticleId IdType="pmc">PMC10660147</ArticleId><ArticleId IdType="pubmed">37202220</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Tang Y., Lin T., Song T. Risk factors and outcomes of IgA nephropathy recurrence after kidney transplantation: A systematic review and meta-analysis. Front. Immunol. 2023;14:1277017. doi: 10.3389/fimmu.2023.1277017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1277017</ArticleId><ArticleId IdType="pmc">PMC10713786</ArticleId><ArticleId IdType="pubmed">38090563</ArticleId></ArticleIdList></Reference><Reference><Citation>Bia M., Adey D.B., Bloom R.D., Chan L., Kulkarni S., Tomlanovich S. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Kidney Dis. 2010;56:189&#x2013;218. doi: 10.1053/j.ajkd.2010.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2010.04.010</ArticleId><ArticleId IdType="pubmed">20598411</ArticleId></ArticleIdList></Reference><Reference><Citation>Lionaki S., Makropoulos I., Panagiotellis K., Vlachopanos G., Gavalas I., Marinaki S., Liapis G., Michelakis I., Bokos I., Boletis I., et al. Kidney transplantation outcomes in patients with IgA nephropathy and other glomerular and non-glomerular primary diseases in the new era of immunosuppression. PLoS ONE. 2021;16:e0253337. doi: 10.1371/journal.pone.0253337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0253337</ArticleId><ArticleId IdType="pmc">PMC8370606</ArticleId><ArticleId IdType="pubmed">34403416</ArticleId></ArticleIdList></Reference><Reference><Citation>Berthelot L., Robert T., Vuiblet V., Tabary T., Braconnier A., Dram&#xe9; M., Toupance O., Rieu P., Monteiro R.C., Tour&#xe9; F. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes. Kidney Int. 2015;88:815&#x2013;822. doi: 10.1038/ki.2015.158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2015.158</ArticleId><ArticleId IdType="pubmed">26061544</ArticleId></ArticleIdList></Reference><Reference><Citation>Garnier A.-S., Duveau A., Demiselle J., Crou&#xe9; A., Subra J.-F., Sayegh J., Augusto J.-F., Moura I.C. Early post-transplant serum IgA level is associated with IgA nephropathy recurrence after kidney transplantation. PLoS ONE. 2018;13:e0196101. doi: 10.1371/journal.pone.0196101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0196101</ArticleId><ArticleId IdType="pmc">PMC5919069</ArticleId><ArticleId IdType="pubmed">29694420</ArticleId></ArticleIdList></Reference><Reference><Citation>Maixnerova D., Hruba P., Neprasova M., Bednarova K., Slatinska J., Suchanek M., Kollar M., Novak J., Tesar V., Viklicky O. Outcome of 313 Czech patients with IgA nephropathy after renal transplantation. Front. Immunol. 2021;12:726215. doi: 10.3389/fimmu.2021.726215.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.726215</ArticleId><ArticleId IdType="pmc">PMC8515028</ArticleId><ArticleId IdType="pubmed">34659212</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni G., Belingheri M., Frontini G., Tamborini F., Messa P. Immunoglobulin A Nephropathy. Recurrence After Renal Transplantation. Front. Immunol. 2019;10:1332. doi: 10.3389/fimmu.2019.01332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01332</ArticleId><ArticleId IdType="pmc">PMC6593081</ArticleId><ArticleId IdType="pubmed">31275309</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong S.C., Julian B.A. Post-transplant IgA Nephropathy. Semin. Nephrol. 2024;44:151570. doi: 10.1016/j.semnephrol.2025.151570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semnephrol.2025.151570</ArticleId><ArticleId IdType="pubmed">40087123</ArticleId></ArticleIdList></Reference><Reference><Citation>Messina M., di Vico M.C., Ariaudo C., Mazzucco G., Fop F., Segoloni G.P., Biancone L. Treatment protocol with pulse and oral steroids for IgA Nephropathy after kidney transplantation. J. Nephrol. 2016;29:575&#x2013;583. doi: 10.1007/s40620-016-0314-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40620-016-0314-5</ArticleId><ArticleId IdType="pubmed">27217158</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra P.S., Jorna T., Bhandari S. Treatment of immunoglobulin A nephropathy recurrence post&#x2013;renal transplant. Transplant. Proc. 2018;50:165&#x2013;167. doi: 10.1016/j.transproceed.2017.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transproceed.2017.12.016</ArticleId><ArticleId IdType="pubmed">29407303</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumlin J.A., Lohavichan V., Hennigar R. Crescentic, proliferative IgA nephropathy: Clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol. Dial. Transplant. 2003;18:1321&#x2013;1329. doi: 10.1093/ndt/gfg081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfg081</ArticleId><ArticleId IdType="pubmed">12808169</ArticleId></ArticleIdList></Reference><Reference><Citation>Roccatello D., Ferro M., Cesano G., Rossi D., Berutti S., Salomone M., Piccoli G., Sena L.M. Steroid and cyclophosphamide in IgA nephropathy. Nephrol. Dial. Transplant. 2000;15:833&#x2013;835. doi: 10.1093/ndt/15.6.833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/15.6.833</ArticleId><ArticleId IdType="pubmed">10831636</ArticleId></ArticleIdList></Reference><Reference><Citation>Chancharoenthana W., Leelahavanichkul A., Ariyanon W., Vadcharavivad S., Phumratanaprapin W. Comparative long-term renal allograft outcomes of recurrent immunoglobulin A with severe activity in kidney transplant recipients with and without rituximab: An observational cohort study. J. Clin. Med. 2021;10:3939. doi: 10.3390/jcm10173939.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10173939</ArticleId><ArticleId IdType="pmc">PMC8432075</ArticleId><ArticleId IdType="pubmed">34501386</ArticleId></ArticleIdList></Reference><Reference><Citation>Chancharoenthana W., Townamchai N., Leelahavanichkul A., Wattanatorn S., Kanjanabuch T., Avihingsanon Y., Praditpornsilpa K., Eiam-Ong S. Rituximab for recurrent IgA nephropathy in kidney transplantation: A report of three cases and proposed mechanisms. Nephrology. 2017;22:65&#x2013;71. doi: 10.1111/nep.12722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nep.12722</ArticleId><ArticleId IdType="pubmed">26758857</ArticleId></ArticleIdList></Reference><Reference><Citation>Duval A., Olagne J., Obrecht A., Vargas G.G., Perrin P., Moulin B., Fr&#xe9;meaux-Bacchi V., Caillard S. Eculizumab as a therapeutic approach for severe crescentic recurrence of immunoglobulin A nephropathy after kidney transplantation. Am. J. Transplant. 2023;23:1626&#x2013;1630. doi: 10.1016/j.ajt.2023.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajt.2023.05.031</ArticleId><ArticleId IdType="pubmed">37268295</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawabe M., Yamamoto I., Yamakawa T., Katsumata H., Isaka N., Katsuma A., Koike K., Ueda H. Association between galactose-deficient IgA1 derived from the tonsils and recurrence of IgA nephropathy in patients who underwent kidney transplantation. Front. Immunol. 2020;11:2068. doi: 10.3389/fimmu.2020.02068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.02068</ArticleId><ArticleId IdType="pmc">PMC7494805</ArticleId><ArticleId IdType="pubmed">33013875</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi H., Tsuchimoto A., Ueki K., Kaku K., Okabe Y., Nakamura M. Reduced recurrence of primary IgA nephropathy in kidney transplant recipients receiving everolimus with corticosteroid: A retrospective, single-center study of 135 transplant patients. Transplant. Proc. 2020;52:3118&#x2013;3124. doi: 10.1016/j.transproceed.2020.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transproceed.2020.05.022</ArticleId><ArticleId IdType="pubmed">32600641</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki Y. B cell targeting in IgA nephropathy. Nephrology. 2024;29((Suppl. S2)):39&#x2013;43. doi: 10.1111/nep.14367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nep.14367</ArticleId><ArticleId IdType="pubmed">39327767</ArticleId></ArticleIdList></Reference><Reference><Citation>El Karoui K., Fervenza F.C., De Vriese A.S. Treatment of IgA Nephropathy: A Rapidly Evolving Field. J. Am. Soc. Nephrol. 2024;35:103&#x2013;116. doi: 10.1681/ASN.0000000000000242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.0000000000000242</ArticleId><ArticleId IdType="pmc">PMC10786616</ArticleId><ArticleId IdType="pubmed">37772889</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabaka A., Tato Ribera A., Fern&#xe1;ndez-Ju&#xe1;rez G. Focal segmental glomerulosclerosis: State-of-the-art and clinical perspective. Nephron. 2020;144:413&#x2013;427. doi: 10.1159/000508099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000508099</ArticleId><ArticleId IdType="pubmed">32721952</ArticleId></ArticleIdList></Reference><Reference><Citation>Battelino N., Arnol M., Kandus A., Ponikvar R., Novljan G. Post-transplant recurrence of focal segmental glomerulosclerosis in a child with heterozygous mutations in NPHS1 and NPHS2. Ther. Apher. Dial. 2016;20:312&#x2013;317. doi: 10.1111/1744-9987.12443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1744-9987.12443</ArticleId><ArticleId IdType="pubmed">27312921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kienzl-Wagner K., Waldegger S., Schneeberger S. Disease recurrence-the sword of Damocles in kidney transplantation for primary focal segmental glomerulosclerosis. Front. Immunol. 2019;10:1669. doi: 10.3389/fimmu.2019.01669.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01669</ArticleId><ArticleId IdType="pmc">PMC6652209</ArticleId><ArticleId IdType="pubmed">31379860</ArticleId></ArticleIdList></Reference><Reference><Citation>Puttarajappa C.M., Schinstock C.A., Wu C.M., Leca N., Kumar V., Vasudev B.S., Hariharan S. KDOQI US commentary on the 2020 KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Am. J. Kidney Dis. 2021;77:833&#x2013;856. doi: 10.1053/j.ajkd.2020.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2020.11.017</ArticleId><ArticleId IdType="pubmed">33745779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D.K., Huh H., Kim Y., Kim T., Kim Y.H., Choi B.H., Lee H.J., Kang M.S., Kim S.R., Lee D.W., et al. Recurrent and DE Novo focal segmental glomerulosclerosis after kidney transplantation: Comparison of clinical features and transplant outcomes. Transplant. Proc. 2024;56:1752&#x2013;1756. doi: 10.1016/j.transproceed.2024.08.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transproceed.2024.08.026</ArticleId><ArticleId IdType="pubmed">39232925</ArticleId></ArticleIdList></Reference><Reference><Citation>Uffing A., P&#xe9;rez-S&#xe1;ez M.J., Mazzali M., Manfro R.C., Bauer A.C., de Sottomaior Drumond F., O&#x2019;sHaughnessy M.M., Cheng X.S., Chin K.-K., Ventura C.G., et al. Recurrence of FSGS after kidney transplantation in adults. Clin. J. Am. Soc. Nephrol. 2020;15:247&#x2013;256. doi: 10.2215/CJN.08970719.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.08970719</ArticleId><ArticleId IdType="pmc">PMC7015092</ArticleId><ArticleId IdType="pubmed">31974287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai J., Zhang T., Wang Y., Cao J., Duan Z., Ji L., Zhou Y., Hao C., Guo Q. Incidence and risk factors for recurrent focal segmental glomerulosclerosis after kidney transplantation: A meta-analysis. Ren. Fail. 2023;45:2201341. doi: 10.1080/0886022X.2023.2201341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0886022X.2023.2201341</ArticleId><ArticleId IdType="pmc">PMC10120546</ArticleId><ArticleId IdType="pubmed">37070350</ArticleId></ArticleIdList></Reference><Reference><Citation>Batal I., Watts A.J.B., Gibier J.-B., Hamroun A., Top I., Provot F., Keller K., Ye X., Fernandez H.E., Leal R., et al. Pre-transplant anti-nephrin antibodies are specific predictors of recurrent diffuse podocytopathy in the kidney allograft. Kidney Int. 2024;106:749&#x2013;752. doi: 10.1016/j.kint.2024.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2024.07.022</ArticleId><ArticleId IdType="pmc">PMC11416305</ArticleId><ArticleId IdType="pubmed">39127225</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirai Y., Miura K., Ishizuka K., Ando T., Kanda S., Hashimoto J., Hamasaki Y., Hotta K., Ito N., Honda K., et al. A multi-institutional study found a possible role of anti-nephrin antibodies in post-transplant focal segmental glomerulosclerosis recurrence. Kidney Int. 2024;105:608&#x2013;617. doi: 10.1016/j.kint.2023.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2023.11.022</ArticleId><ArticleId IdType="pubmed">38110152</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao T., Udwan K., John R., Rana A., Haghighi A., Xu L., Hack S., Reich H.N., Hladunewich M.A., Cattran D.C., et al. Integration of genetic testing and pathology for the diagnosis of adults with FSGS. Clin. J. Am. Soc. Nephrol. 2019;14:213&#x2013;223. doi: 10.2215/CJN.08750718.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.08750718</ArticleId><ArticleId IdType="pmc">PMC6390925</ArticleId><ArticleId IdType="pubmed">30647093</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vriese A.S., Sethi S., Nath K.A., Glassock R.J., Fervenza F.C. Differentiating primary, genetic, and secondary FSGS in adults: A clinicopathologic approach. J. Am. Soc. Nephrol. 2018;29:759&#x2013;774. doi: 10.1681/ASN.2017090958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2017090958</ArticleId><ArticleId IdType="pmc">PMC5827609</ArticleId><ArticleId IdType="pubmed">29321142</ArticleId></ArticleIdList></Reference><Reference><Citation>Canaud G., Dion D., Zuber J., Gubler M.-C., Sberro R., Thervet E., Snanoudj R., Charbit M., Salomon R., Martinez F., et al. Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: Course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS) Nephrol. Dial. Transplant. 2010;25:1321&#x2013;1328. doi: 10.1093/ndt/gfp500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfp500</ArticleId><ArticleId IdType="pubmed">19773419</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiser J., Nast C.C., Alachkar N. Permeability factors in focal and segmental glomerulosclerosis. Adv. Chronic Kidney Dis. 2014;21:417&#x2013;421. doi: 10.1053/j.ackd.2014.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ackd.2014.05.010</ArticleId><ArticleId IdType="pmc">PMC4149759</ArticleId><ArticleId IdType="pubmed">25168830</ArticleId></ArticleIdList></Reference><Reference><Citation>Andresdottir M.B., Ajubi N., Croockewit S., Assmann K.J., Hibrands L.B., Wetzels J.F. Recurrent focal glomerulosclerosis: Natural course and treatment with plasma exchange. Nephrol. Dial. Transplant. 1999;14:2650&#x2013;2656. doi: 10.1093/ndt/14.11.2650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/14.11.2650</ArticleId><ArticleId IdType="pubmed">10534507</ArticleId></ArticleIdList></Reference><Reference><Citation>Savin V.J., Sharma R., Sharma M., McCarthy E.T., Swan S.K., Ellis E., Lovell H., Warady B., Gunwar S., Chonko A.M., et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N. Engl. J. Med. 1996;334:878&#x2013;883. doi: 10.1056/NEJM199604043341402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199604043341402</ArticleId><ArticleId IdType="pubmed">8596570</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma M., Sharma R., Reddy S.R., McCarthy E.T., Savin V.J. Proteinuria after injection of human focal segmental glomerulosclerosis factor. Transplantation. 2002;73:366&#x2013;372. doi: 10.1097/00007890-200202150-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007890-200202150-00009</ArticleId><ArticleId IdType="pubmed">11884932</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y., Shah S., Campbell K.N. Molecular mechanisms of proteinuria in focal segmental glomerulosclerosis. Front. Med. 2018;5:98. doi: 10.3389/fmed.2018.00098.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2018.00098</ArticleId><ArticleId IdType="pmc">PMC5912003</ArticleId><ArticleId IdType="pubmed">29713631</ArticleId></ArticleIdList></Reference><Reference><Citation>Hengel F.E., Dehde S., Lass&#xe9; M., Zahner G., Seifert L., Schnarre A., Kretz O., Demir F., Pinnschmidt H.O., Grahammer F., et al. Autoantibodies Targeting Nephrin in Podocytopathies. N. Engl. J. Med. 2024;391:422&#x2013;433. doi: 10.1056/NEJMoa2314471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2314471</ArticleId><ArticleId IdType="pubmed">38804512</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu Y., Huang J., Jiang L., Zhang Y.-M., Wang F., Wang X., Meng L.-Q., Cheng X.-Y., Liu G., Wang S.-X., et al. Anti-nephrin antibodies in adult Chinese patients with minimal change disease and primary focal segmental glomerulosclerosis. Kidney Int. 2025;108:433&#x2013;444. doi: 10.1016/j.kint.2025.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2025.02.028</ArticleId><ArticleId IdType="pubmed">40147632</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadban S.J., Ahn C., Axelrod D.A., Foster B.J., Kasiske B.L., Kher V., Kumar D.M., Oberbauer R., Pascual J., Pilmore H.L., et al. Summary of the kidney disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the evaluation and Management of candidates for Kidney Transplantation. Transplantation. 2020;104:708&#x2013;714. doi: 10.1097/TP.0000000000003137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000003137</ArticleId><ArticleId IdType="pmc">PMC7147399</ArticleId><ArticleId IdType="pubmed">32224812</ArticleId></ArticleIdList></Reference><Reference><Citation>Campise M., Favi E., Messa P. Clinical outcomes of prophylactic and therapeutic plasmapheresis in adult deceased-donor kidney transplant recipients with primary focal segmental glomerulosclerosis. Exp. Clin. Transplant. 2019;17:461&#x2013;469. doi: 10.6002/ect.2018.0106.</Citation><ArticleIdList><ArticleId IdType="doi">10.6002/ect.2018.0106</ArticleId><ArticleId IdType="pubmed">30570457</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon H.E., Kim Y.H., Lee S.A., Lee J.J., Ko Y., Shin S., Jung J.H., Sung F.S., Baek C.H., Kim H., et al. Post-operative recurrence of focal segmental glomerulosclerosis according to pre-transplant treatment after kidney transplantation. BMC Nephrol. 2023;24:53. doi: 10.1186/s12882-023-03098-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-023-03098-1</ArticleId><ArticleId IdType="pmc">PMC10018840</ArticleId><ArticleId IdType="pubmed">36922759</ArticleId></ArticleIdList></Reference><Reference><Citation>Boonpheng B., Hansrivijit P., Thongprayoon C., Mao S.A., Vaitla P.K., Bathini T., Choudhury A., Kaewput W., A Mao M., Cheungpasitporn W. Rituximab or plasmapheresis for prevention of recurrent focal segmental glomerulosclerosis after kidney transplantation: A systematic review and meta-analysis. World J. Transplant. 2021;11:303&#x2013;319. doi: 10.5500/wjt.v11.i7.303.</Citation><ArticleIdList><ArticleId IdType="doi">10.5500/wjt.v11.i7.303</ArticleId><ArticleId IdType="pmc">PMC8291000</ArticleId><ArticleId IdType="pubmed">34316454</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornoni A., Sageshima J., Wei C., Merscher-Gomez S., Aguillon-Prada R., Jauregui A.N., Li J., Mattiazzi A., Ciancio G., Chen L., et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci. Transl. Med. 2011;3:85ra46. doi: 10.1126/scitranslmed.3002231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002231</ArticleId><ArticleId IdType="pmc">PMC3719858</ArticleId><ArticleId IdType="pubmed">21632984</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronbichler A., Gauckler P., Lee K.H., Shin J.I., Malvezzi P., Mayer G. Immunoadsorption in nephrotic syndrome: Where are we now and where are we going from here? Atheroscler. Suppl. 2019;40:55&#x2013;60. doi: 10.1016/j.atherosclerosissup.2019.08.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosissup.2019.08.027</ArticleId><ArticleId IdType="pubmed">31447217</ArticleId></ArticleIdList></Reference><Reference><Citation>Allard L., Kwon T., Krid S., Bacchetta J., Garnier A., Novo R., Deschenes G., Salomon R., Roussey G., Allain-Launay E. Treatment by immunoadsorption for recurrent focal segmental glomerulosclerosis after paediatric kidney transplantation: A multicentre French cohort. Nephrol. Dial. Transplant. 2018;33:954&#x2013;963. doi: 10.1093/ndt/gfx214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfx214</ArticleId><ArticleId IdType="pubmed">28992235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanaret C., Anglicheau D., Audard V., B&#xfc;chler M., Caillard S., Couzi L., Malvezzi P., Mesnard L., Bertrand D., Martinez F., et al. Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study. Am. J. Transplant. 2021;21:3021&#x2013;3033. doi: 10.1111/ajt.16504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16504</ArticleId><ArticleId IdType="pubmed">33512779</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhamad T., Manllo Dieck J., Younus U., Matar D., Alasfar S., Vujjini V., Wall D., Kanawati B., Reiser J., Brennan D.C., et al. ACTH gel in resistant focal segmental glomerulosclerosis after kidney transplantation. Transplantation. 2019;103:202&#x2013;209. doi: 10.1097/TP.0000000000002320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000002320</ArticleId><ArticleId IdType="pubmed">29894413</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Wu J., Ying D., Jiang M., Xu Y., Mo Y., Rong L., Jiang X. Application of adrenocorticotropic hormone in recurrent focal segmental glomerulosclerosis post-transplantation: A case report and literature review. Pediatr. Transplant. 2022;26:e14184. doi: 10.1111/petr.14184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/petr.14184</ArticleId><ArticleId IdType="pubmed">34724313</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah L., Hooper D.K., Okamura D., Wallace D., Moodalbail D., Gluck C., Koziell A., Zaritsky J.J. LDL-apheresis-induced remission of focal segmental glomerulosclerosis recurrence in pediatric renal transplant recipients. Pediatr. Nephrol. 2019;34:2343&#x2013;2350. doi: 10.1007/s00467-019-04296-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-019-04296-6</ArticleId><ArticleId IdType="pubmed">31250206</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina R., Krishnappa V. An update on LDL apheresis for nephrotic syndrome. Pediatr. Nephrol. 2019;34:1655&#x2013;1669. doi: 10.1007/s00467-018-4061-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-018-4061-9</ArticleId><ArticleId IdType="pubmed">30218191</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianos E., Duell P.B., Toth P.P., Moriarty P.M., Thompson G.R., Brinton E.A., Hudgins L.C., Nametka M., Byrne K.H., Raghuveer G., et al. Lipoprotein apheresis: Utility, outcomes, and implementation in clinical practice: A scientific statement from the American heart association. Arterioscler. Thromb. Vasc. Biol. 2024;44:e304&#x2013;e321. doi: 10.1161/ATV.0000000000000177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATV.0000000000000177</ArticleId><ArticleId IdType="pubmed">39370995</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds B.C., Lamb A., Jones C.A., Yadav P., Tyerman K.S., Geddes C.C. UK experience of ofatumumab in recurrence of focal segmental glomerulosclerosis post-kidney transplant. Pediatr. Nephrol. 2022;37:199&#x2013;207. doi: 10.1007/s00467-021-05248-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-021-05248-9</ArticleId><ArticleId IdType="pmc">PMC8674165</ArticleId><ArticleId IdType="pubmed">34383125</ArticleId></ArticleIdList></Reference><Reference><Citation>Ural Z., Helvac&#x131; &#xd6;., &#xd6;zba&#x15f; B., G&#xfc;z G., Derici &#xdc;. Unexpected late response to ofatumumab in adult post-transplantation recurrent focal segmental glomerulosclerosis, case report. Transplant. Proc. 2022;54:1632&#x2013;1635. doi: 10.1016/j.transproceed.2022.04.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transproceed.2022.04.019</ArticleId><ArticleId IdType="pubmed">35853766</ArticleId></ArticleIdList></Reference><Reference><Citation>Batal I., Vasilescu E.-R., Dadhania D.M., Adel A.A., Husain S.A., Avasare R., Serban G., Santoriello D., Khairallah P., Patel A., et al. Association of HLA typing and alloimmunity with posttransplantation membranous nephropathy: A multicenter case series. Am. J. Kidney Dis. 2020;76:374&#x2013;383. doi: 10.1053/j.ajkd.2020.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2020.01.009</ArticleId><ArticleId IdType="pmc">PMC7483441</ArticleId><ArticleId IdType="pubmed">32359820</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponticelli C., Glassock R.J. De novo membranous nephropathy (MN) in kidney allografts. A peculiar form of alloimmune disease? Transpl. Int. 2012;25:1205&#x2013;1210. doi: 10.1111/j.1432-2277.2012.01548.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1432-2277.2012.01548.x</ArticleId><ArticleId IdType="pubmed">22909324</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagakis A., Bellos I., Grigorakos K., Panagoutsos S., Passadakis P., Marinaki S. Recurrence of idiopathic membranous nephropathy in the kidney allograft: A systematic review. Biomedicines. 2024;12:739. doi: 10.3390/biomedicines12040739.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines12040739</ArticleId><ArticleId IdType="pmc">PMC11048506</ArticleId><ArticleId IdType="pubmed">38672095</ArticleId></ArticleIdList></Reference><Reference><Citation>Hullekes F., Uffing A., Verhoeff R., Seeger H., von Moos S., Mansur J., Mastroianni-Kirsztajn G., Silva H.T., Buxeda A., P&#xe9;rez-S&#xe1;ez M.J., et al. Recurrence of membranous nephropathy after kidney transplantation: A multicenter retrospective cohort study. Am. J. Transplant. 2024;24:1016&#x2013;1026. doi: 10.1016/j.ajt.2024.01.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajt.2024.01.036</ArticleId><ArticleId IdType="pubmed">38341027</ArticleId></ArticleIdList></Reference><Reference><Citation>Grupper A., Cornell L.D., Fervenza F.C., Beck L.H., Jr., Lorenz E., Cosio F.G. Recurrent membranous nephropathy after kidney transplantation: Treatment and long-term implications. Transplantation. 2016;100:2710&#x2013;2716. doi: 10.1097/TP.0000000000001056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000001056</ArticleId><ArticleId IdType="pubmed">26720301</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremoni M., Teisseyre M., Thaunat O., Fernandez C., Payre C., Moutou A., Zarif H., Brglez V., Albano L., Moal V., et al. Anti phospholipase A2 receptor 1 antibodies and membranous nephropathy recurrence after kidney transplantation. Kidney Int. Rep. 2024;9:3427&#x2013;3438. doi: 10.1016/j.ekir.2024.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2024.09.012</ArticleId><ArticleId IdType="pmc">PMC11652070</ArticleId><ArticleId IdType="pubmed">39698349</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson K.J., Kitching A.R. Recurrent membranous nephropathy after transplantation: Donor antigen and HLA converge in defining risk. Kidney Int. 2021;99:545&#x2013;548. doi: 10.1016/j.kint.2020.10.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.10.044</ArticleId><ArticleId IdType="pubmed">33637201</ArticleId></ArticleIdList></Reference><Reference><Citation>Berchtold L., Letouz&#xe9; E., Alexander M.P., Canaud G., Logt A-Evan de Hamilton P., Mousson C., Vuiblet V., Moyer A.M., Guibert S. HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. Kidney Int. 2021;99:671&#x2013;685. doi: 10.1016/j.kint.2020.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.08.007</ArticleId><ArticleId IdType="pubmed">32889013</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon J., P&#xe9;rez-S&#xe1;ez M.J., Batal I., Beck L.H., Jr., Rennke H.G., Canaud G., Legendre C., Pascual J., Riella L.V. Membranous nephropathy posttransplantation: An update of the pathophysiology and management. Transplantation. 2019;103:1990&#x2013;2002. doi: 10.1097/TP.0000000000002758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000002758</ArticleId><ArticleId IdType="pubmed">31568231</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippone E.J., Farber J.L. Membranous nephropathy in the kidney allograft. Clin. Transplant. 2016;30:1394&#x2013;1402. doi: 10.1111/ctr.12847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ctr.12847</ArticleId><ArticleId IdType="pubmed">27646575</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin B.H., Adler S.G., Barratt J., Bridoux F., Burdge K.A., Chan T.M., Cook H.T., Fervenza F.C., Gibson K.L., Glassock R.J., et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:S1&#x2013;S276. doi: 10.1016/j.kint.2021.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.021</ArticleId><ArticleId IdType="pubmed">34556256</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng L., Xu G. Update on the application of monoclonal antibody therapy in primary membranous nephropathy. Drugs. 2023;83:507&#x2013;530. doi: 10.1007/s40265-023-01855-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-023-01855-y</ArticleId><ArticleId IdType="pubmed">37017915</ArticleId></ArticleIdList></Reference><Reference><Citation>Delbet J.-D., Hogan J., Parmentier C., Ulinski T., Dossier C. Successful global anti-B-cell strategy with daratumumab in a patient with post-transplant nephrotic syndrome recurrence unresponsive to immunoadsorption and obinutuzumab. Pediatr. Transplant. 2023;27:e14544. doi: 10.1111/petr.14544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/petr.14544</ArticleId><ArticleId IdType="pubmed">37226549</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethi S., Kumar S., Lim K., Jordan S.C. Obinutuzumab is effective for the treatment of refractory membranous nephropathy. Kidney Int. Rep. 2020;5:1515&#x2013;1518. doi: 10.1016/j.ekir.2020.06.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2020.06.030</ArticleId><ArticleId IdType="pmc">PMC7486170</ArticleId><ArticleId IdType="pubmed">32954076</ArticleId></ArticleIdList></Reference><Reference><Citation>Alasfar S., Carter-Monroe N., Rosenberg A.Z., Montgomery R.A., Alachkar N. Membranoproliferative glomerulonephritis recurrence after kidney transplantation: Using the new classification. BMC Nephrol. 2016;17:7. doi: 10.1186/s12882-015-0219-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-015-0219-x</ArticleId><ArticleId IdType="pmc">PMC4709883</ArticleId><ArticleId IdType="pubmed">26754737</ArticleId></ArticleIdList></Reference><Reference><Citation>Caravaca-Font&#xe1;n F., Polanco N., Villacorta B., Buxeda A., Coca A., &#xc1;vila A., Mart&#xed;nez-Gallardo R., Galeano C., Valero R., Ramos N., et al. Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation. Nephrol. Dial. Transplant. 2023;38:222&#x2013;235. doi: 10.1093/ndt/gfac148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfac148</ArticleId><ArticleId IdType="pubmed">35404425</ArticleId></ArticleIdList></Reference><Reference><Citation>Attieh R.M., Bharati J., Sharma P., Nair G., Ayehu G., Jhaveri K.D. Kidney transplant in patients with C3 glomerulopathy. Clin Kidney J. 2025;18:sfaf134. doi: 10.1093/ckj/sfaf134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ckj/sfaf134</ArticleId><ArticleId IdType="pmc">PMC12082085</ArticleId><ArticleId IdType="pubmed">40385590</ArticleId></ArticleIdList></Reference><Reference><Citation>Chukwu C.A., Holmberg C., Storrar J., Middleton R., Sinha S., Kalra P.A., Shawki H., Rao A. Clinical and histopathologic predictors of recurrent glomerulonephritis after kidney transplantation. Clin. Transplant. 2023;37:e14970. doi: 10.1111/ctr.14970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ctr.14970</ArticleId><ArticleId IdType="pubmed">36950848</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun M.C., Stablein D.M., Hamiwka L.A., Bell L., Bartosh S.M., Strife C.F. Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience. J. Am. Soc. Nephrol. 2005;16:2225&#x2013;2233. doi: 10.1681/ASN.2005020175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2005020175</ArticleId><ArticleId IdType="pubmed">15888559</ArticleId></ArticleIdList></Reference><Reference><Citation>Green H., Rahamimov R., Rozen-Zvi B., Pertzov B., Tobar A., Lichtenberg S., Gafter U., Mor E. Recurrent membranoproliferative glomerulonephritis type I after kidney transplantation: A 17-year single-center experience. Transplantation. 2015;99:1172&#x2013;1177. doi: 10.1097/TP.0000000000000459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000000459</ArticleId><ArticleId IdType="pubmed">25340602</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartoli G., Dello Strologo A., Grandaliano G., Pesce F. Updates on C3 glomerulopathy in kidney transplantation: Pathogenesis and treatment options. Int. J. Mol. Sci. 2024;25:6508. doi: 10.3390/ijms25126508.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25126508</ArticleId><ArticleId IdType="pmc">PMC11204074</ArticleId><ArticleId IdType="pubmed">38928213</ArticleId></ArticleIdList></Reference><Reference><Citation>Regunathan-Shenk R., Avasare R.S., Ahn W., Canetta P.A., Cohen D.J., Appel G.B., Bomback A.S. Kidney transplantation in C3 glomerulopathy: A case series. Am. J. Kidney Dis. 2019;73:316&#x2013;323. doi: 10.1053/j.ajkd.2018.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2018.09.002</ArticleId><ArticleId IdType="pubmed">30413277</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg N., Zhang Y., Nicholson-Weller A., Khankin E.V., Borsa N.G., Meyer N.C., McDermott S., Stillman I.E., Rennke H.G., Smith R.J., et al. C3 glomerulonephritis secondary to mutations in factors H and I: Rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab. Nephrol. Dial. Transplant. 2018;33:2260&#x2013;2265. doi: 10.1093/ndt/gfx369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfx369</ArticleId><ArticleId IdType="pmc">PMC6275145</ArticleId><ArticleId IdType="pubmed">29370420</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.J.H., Appel G.B., Blom A.M., Cook H.T., D&#x2019;Agati V.D., Fakhouri F., Fremeaux-Bacchi V., J&#xf3;zsi M., Kavanagh D., Lambris J.D., et al. C3 glomerulopathy&#x2014;Understanding a rare complement-driven renal disease. Nat. Rev. Nephrol. 2019;15:129&#x2013;143. doi: 10.1038/s41581-018-0107-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-018-0107-2</ArticleId><ArticleId IdType="pmc">PMC6876298</ArticleId><ArticleId IdType="pubmed">30692664</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz F., Singh T., Garg N., Zhong W., Mandelbrot D. Post-Transplant Idiopathic Immune Complex Membrano-Proliferative Glomerulonephritis: Characteristics And outcomes. Clin. Nephrol. 2023;99:69&#x2013;77. doi: 10.5414/CN110991.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/CN110991</ArticleId><ArticleId IdType="pubmed">36519938</ArticleId></ArticleIdList></Reference><Reference><Citation>Yango A.F., Fischbach B.V., Ruiz R., Mudrovich S., Klintmalm G. Treatment Of Recurrent, Post-Kidney Transplant Membranoproliferative Glomerulonephritis With Plasmapheresis and Rituximab: A Case Report and Literature Review. Clin. Nephrol. 2019;91:52&#x2013;58. doi: 10.5414/CN109451.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/CN109451</ArticleId><ArticleId IdType="pubmed">30431428</ArticleId></ArticleIdList></Reference><Reference><Citation>Lien Y.H., Scott K. Long-term cyclophosphamide treatment for recurrent type I membranoproliferative glomerulonephritis after transplantation. Am. J. Kidney Dis. 2000;35:539&#x2013;543. doi: 10.1016/S0272-6386(00)70211-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0272-6386(00)70211-3</ArticleId><ArticleId IdType="pubmed">10692284</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck L.H., Jr., Ayoub I., Caster D., Choi M.J., Cobb J., Geetha D., Rheault M.N., Wadhwani S., Yau T., Whittier W.L. KDOQI US commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases. Am. J. Kidney Dis. 2023;82:121&#x2013;175. doi: 10.1053/j.ajkd.2023.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2023.02.003</ArticleId><ArticleId IdType="pubmed">37341661</ArticleId></ArticleIdList></Reference><Reference><Citation>McCaughan J.A., O&#x2019;Rourke D.M., Courtney A.E. Recurrent dense deposit disease after renal transplantation: An emerging role for complementary therapies. Am. J. Transplant. 2012;12:1046&#x2013;1051. doi: 10.1111/j.1600-6143.2011.03923.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2011.03923.x</ArticleId><ArticleId IdType="pubmed">22233157</ArticleId></ArticleIdList></Reference><Reference><Citation>Troise D., Infante B., Mercuri S., Rossini M., Gesualdo L., Stallone G. Successful management of C3 glomerulopathy recurrence post-kidney transplantation with Iptacopan: A case report. Int. J. Mol. Sci. 2025;26:5053. doi: 10.3390/ijms26115053.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms26115053</ArticleId><ArticleId IdType="pmc">PMC12154424</ArticleId><ArticleId IdType="pubmed">40507864</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso M.C., Cugno M., Griffini S., Grovetti E., Nittoli T., Mastrangelo A., Tedesco F., Montini G., Ardissino G. Efficacy of complement inhibition with pegcetacoplan in children with C3 glomerulopathy. Pediatr. Nephrol. 2025;40:1959&#x2013;1963. doi: 10.1007/s00467-025-06673-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-025-06673-w</ArticleId><ArticleId IdType="pubmed">39841237</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman G.L., Perry K.W. Pegcetacoplan for the treatment of paediatric C3 glomerulonephritis: A case report. Nephrology. 2025;30:e70001. doi: 10.1111/nep.70001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nep.70001</ArticleId><ArticleId IdType="pmc">PMC11772912</ArticleId><ArticleId IdType="pubmed">39871447</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomback A.S., Daina E., Remuzzi G., Kanellis J., Kavanagh D., Pickering M.C., Sunder-Plassmann G., Walker P.D., Wang Z., Ahmad Z., et al. Efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent complement 3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis. Kidney Int. Rep. 2025;10:87&#x2013;98. doi: 10.1016/j.ekir.2024.09.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2024.09.030</ArticleId><ArticleId IdType="pmc">PMC11725963</ArticleId><ArticleId IdType="pubmed">39810766</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarrag&#xf3;n B., Peleg Y., Jagannathan G., Sekulic M., Chang J.-H., Cohen D.J., Crew R.J., Dube G.K., Fernandez H.E., Husain S.A., et al. C3 glomerulopathy recurs early after kidney transplantation in serial biopsies performed within the first 2 years after transplantation. Clin. J. Am. Soc. Nephrol. 2024;19:1005&#x2013;1015. doi: 10.2215/CJN.0000000000000474.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.0000000000000474</ArticleId><ArticleId IdType="pmc">PMC11321730</ArticleId><ArticleId IdType="pubmed">39116277</ArticleId></ArticleIdList></Reference><Reference><Citation>Infante B., Rossini M., Leo S., Troise D., Netti G.S., Ranieri E., Gesualdo L., Castellano G., Stallone G. Recurrent glomerulonephritis after renal transplantation: The clinical problem. Int. J. Mol. Sci. 2020;21:5954. doi: 10.3390/ijms21175954.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21175954</ArticleId><ArticleId IdType="pmc">PMC7504691</ArticleId><ArticleId IdType="pubmed">32824988</ArticleId></ArticleIdList></Reference><Reference><Citation>Noris M., Remuzzi G. C3G and Ig-MPGN-treatment standard. Nephrol. Dial. Transplant. 2024;39:202&#x2013;214. doi: 10.1093/ndt/gfad182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfad182</ArticleId><ArticleId IdType="pmc">PMC10828209</ArticleId><ArticleId IdType="pubmed">37604793</ArticleId></ArticleIdList></Reference><Reference><Citation>Coche S., Sprangers B., Van Laecke S., Weekers L., De Meyer V., Hellemans R., Castanares D., Ameye H., Goffin E., Demoulin N., et al. Recurrence and outcome of anti-glomerular basement membrane glomerulonephritis after kidney transplantation. Kidney Int. Rep. 2021;6:1888&#x2013;1894. doi: 10.1016/j.ekir.2021.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2021.04.011</ArticleId><ArticleId IdType="pmc">PMC8258451</ArticleId><ArticleId IdType="pubmed">34307983</ArticleId></ArticleIdList></Reference><Reference><Citation>Mignano S.E., Nasr S.H., Fidler M.E., Herrera Hernandez L.P., Alexander M.P., Sethi S., Messias N., Alhamad T., Alrata L., Albadri S.T., et al. Recurrent atypical antiglomerular basement membrane nephritis in the kidney transplant. Am. J. Transplant. 2024;24:123&#x2013;133. doi: 10.1016/j.ajt.2023.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajt.2023.09.007</ArticleId><ArticleId IdType="pubmed">37774840</ArticleId></ArticleIdList></Reference><Reference><Citation>Segelmark M., Hellmark T. Anti-glomerular basement membrane disease: An update on subgroups, pathogenesis and therapies. Nephrol. Dial. Transplant. 2019;34:1826&#x2013;1832. doi: 10.1093/ndt/gfy327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfy327</ArticleId><ArticleId IdType="pubmed">30371823</ArticleId></ArticleIdList></Reference><Reference><Citation>McAdoo S.P., Pusey C.D. Anti-glomerular basement membrane disease. Clin. J. Am. Soc. Nephrol. 2017;12:1162&#x2013;1172. doi: 10.2215/CJN.01380217.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.01380217</ArticleId><ArticleId IdType="pmc">PMC5498345</ArticleId><ArticleId IdType="pubmed">28515156</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras G., Mattiazzi A., Guerra G., Ortega L.M., Tozman E.C., Li H., Tamariz L., Carvalho C., Kupin W., Ladino M., et al. Recurrence of lupus nephritis after kidney transplantation. J. Am. Soc. Nephrol. 2010;21:1200&#x2013;1207. doi: 10.1681/ASN.2009101093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2009101093</ArticleId><ArticleId IdType="pmc">PMC3152228</ArticleId><ArticleId IdType="pubmed">20488956</ArticleId></ArticleIdList></Reference><Reference><Citation>Norby G.E., Str&#xf8;m E.H., Midtvedt K., Hartmann A., Gilboe I.-M., Leivestad T., Stenstr&#xf8;m J., Holdaas H. Recurrent lupus nephritis after kidney transplantation: A surveillance biopsy study. Ann. Rheum. Dis. 2010;69:1484&#x2013;1487. doi: 10.1136/ard.2009.122796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2009.122796</ArticleId><ArticleId IdType="pubmed">20498208</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;105:S1&#x2013;S69. doi: 10.1016/j.kint.2023.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2023.09.002</ArticleId><ArticleId IdType="pubmed">38182286</ArticleId></ArticleIdList></Reference><Reference><Citation>Sammaritano L.R., Askanase A., Bermas B.L., Dall&#x2019;Era M., Duarte-Garc&#xed;a A., Hiraki L.T., Rovin B.H., Son M.B.F., Alvarado A., Aranow C., et al. 2024 American college of rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Rheumatol. 2025;77:1115&#x2013;1135. doi: 10.1002/art.43212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.43212</ArticleId><ArticleId IdType="pubmed">40331662</ArticleId></ArticleIdList></Reference><Reference><Citation>Albuquerque B.C., Salles V.B., Tajra RDde P., Rodrigues C.E.M. Outcome and prognosis of patients with lupus nephritis submitted to renal transplantation. Sci. Rep. 2019;9:11611. doi: 10.1038/s41598-019-48070-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48070-y</ArticleId><ArticleId IdType="pmc">PMC6690950</ArticleId><ArticleId IdType="pubmed">31406264</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodelo J., Gonz&#xe1;lez L.A., Ust&#xe1;riz J., Matera S., P&#xe9;rez K., Ram&#xed;rez Z., Arias L.F., Garc&#xed;a &#xc1;., Arbel&#xe1;ez M., Henao J. Kidney transplantation outcomes in lupus nephritis: A 37-year single-center experience from Latin America. Lupus. 2021;30:1644&#x2013;1659. doi: 10.1177/09612033211028663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211028663</ArticleId><ArticleId IdType="pubmed">34225520</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc7;elt&#x130;k A., &#x15e;en S., Tamer A.F., Y&#x131;lmaz M., Sars&#x131;k B., &#xd6;zkahya M., Ba&#x15f;&#xe7;&#x131; A., T&#xf6;z H. Recurrent lupus nephritis after transplantation: Clinicopathological evaluation with protocol biopsies. Nephrology. 2016;21:601&#x2013;607. doi: 10.1111/nep.12657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nep.12657</ArticleId><ArticleId IdType="pubmed">26482014</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni G., Calatroni M., Ponticelli C. The Recurrence of Systemic Diseases in Kidney Transplantation. J. Clin. Med. 2025;14:2592. doi: 10.3390/jcm14082592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm14082592</ArticleId><ArticleId IdType="pmc">PMC12027678</ArticleId><ArticleId IdType="pubmed">40283422</ArticleId></ArticleIdList></Reference><Reference><Citation>Meehan S.M., Chang A., Khurana A., Baliga R., Kadambi P.V., Javaid B. Pauci-immune and immune glomerular lesions in kidney transplants for systemic lupus erythematosus. Clin. J. Am. Soc. Nephrol. 2008;3:1469&#x2013;1478. doi: 10.2215/CJN.00790208.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.00790208</ArticleId><ArticleId IdType="pmc">PMC2518796</ArticleId><ArticleId IdType="pubmed">18562595</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel C.H., Sammaritano L.R. Systemic lupus erythematosus: A review. JAMA. 2024;331:1480&#x2013;1491. doi: 10.1001/jama.2024.2315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2024.2315</ArticleId><ArticleId IdType="pubmed">38587826</ArticleId></ArticleIdList></Reference><Reference><Citation>Masset C., Kandel-Aznar C., Dantal J., Giral M., Hourmant M., Blancho G., Garandeau C. Early and late ANCA vasculitis relapses after kidney transplantation may have different presentations. Clin. Kidney J. 2022;15:1021&#x2013;1023. doi: 10.1093/ckj/sfac016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ckj/sfac016</ArticleId><ArticleId IdType="pmc">PMC9050533</ArticleId><ArticleId IdType="pubmed">35498898</ArticleId></ArticleIdList></Reference><Reference><Citation>Hruskova Z., Geetha D., Tesar V. Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrol. Dial. Transplant. 2015;30((Suppl. 1)):i159&#x2013;i163. doi: 10.1093/ndt/gfu328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfu328</ArticleId><ArticleId IdType="pubmed">25324359</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau D., Summers S., Amos L., Simpson I., Mulley W. Recurrence of anti-neutrophil cytoplasmic antibody vasculitis in the kidney allograft. Nephrology. 2012;17((Suppl. S1)):16&#x2013;19. doi: 10.1111/j.1440-1797.2012.01586.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1797.2012.01586.x</ArticleId><ArticleId IdType="pubmed">22497649</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva R.M., Leal R., Marques M.G., Rodrigues L., Santos L., Rom&#xe3;ozinho C., Alves R., Figueiredo A. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: A single-center 10-year experience. Transplant. Proc. 2023;55:1396&#x2013;1399. doi: 10.1016/j.transproceed.2023.04.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transproceed.2023.04.018</ArticleId><ArticleId IdType="pubmed">37202303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Kidney Int. 2024;105:S71&#x2013;S116. doi: 10.1016/j.kint.2023.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2023.10.008</ArticleId><ArticleId IdType="pubmed">38388102</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;&#xe7;ero&#x11f;lu A., Rahmattulla C., Berden A.E., Reinders M.E.J., Wolterbeek R., Steenbergen E.J., Hilbrands L.B., Noorlander I., Berger S.P., Peutz-Kootstra C.J., et al. The Dutch Transplantation in Vasculitis (DUTRAVAS) Study: Outcome of Renal Transplantation in Antineutrophil Cytoplasmic Antibody-associated Glomerulonephritis. Transplantation. 2016;100:916&#x2013;924. doi: 10.1097/TP.0000000000000910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000000910</ArticleId><ArticleId IdType="pubmed">26371598</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami C., Manoharan P., Carter-Monroe N., Geetha D. Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis postkidney transplant. Transpl. Int. 2013;26:1225&#x2013;1231. doi: 10.1111/tri.12203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tri.12203</ArticleId><ArticleId IdType="pubmed">24118474</ArticleId></ArticleIdList></Reference><Reference><Citation>Geetha D., Seo P., Specks U., Fervenza F.C. Successful induction of remission with rituximab for relapse of ANCA-associated vasculitis post-kidney transplant: Report of two cases. Am. J. Transplant. 2007;7:2821&#x2013;2825. doi: 10.1111/j.1600-6143.2007.01985.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2007.01985.x</ArticleId><ArticleId IdType="pubmed">17908274</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati K., Edwards H., Prendecki M., Cairns T.D., Condon M., Galliford J., Griffith M., Levy J.B., Tam F.W., Tanna A., et al. Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2021;100:1316&#x2013;1324. doi: 10.1016/j.kint.2021.08.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.08.025</ArticleId><ArticleId IdType="pubmed">34560140</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>